<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factor VIII, recombinant human pegylated: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factor VIII, recombinant human pegylated: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Factor VIII, recombinant human pegylated: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="105442" href="/d/html/105442.html" rel="external">see "Factor VIII, recombinant human pegylated: Drug information"</a> and <a class="drug drug_patient" data-topicid="105867" href="/d/html/105867.html" rel="external">see "Factor VIII, recombinant human pegylated: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45755753"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adynovate;</li>
<li>Esperoct;</li>
<li>Jivi</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872102"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Adynovate;</li>
<li>Esperoct;</li>
<li>Jivi</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56777524"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F45760118"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41bca916-fbad-4b58-b634-e51fe53bc8d4">Hemophilia A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A: </b>Individualize dosage based on clinical response and factor VIII activity evaluated at baseline and at regular intervals during treatment. Patients with inhibitory antibodies to factor VIII may require higher doses, more frequent administration, and/or selection of alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing for control and prevention of bleeding episodes or perioperative management: Note: </b>Dosage is expressed in units of factor VIII activity and must be individualized based on formulation, severity of factor VIII deficiency, extent and location of bleed, individualized incremental recovery using factor VIII activity assays, and clinical situation of patient. Product selection is age dependent.</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents (Adynovate, Esperoct) or Children ≥12 years and Adolescents (Jivi): IV: Utilize steps 1 through 3 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 1:</b> Determine desired factor VIII peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. These recommendations reflect WFH guidelines for higher-dose practice patterns; this dosing is typically used in areas where no significant resource constraints exist; recommendations may vary from those found within prescribing information or practitioner preference. Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels (if available) before the next dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<caption style="text-align:left;">
<b>WFH Treatment Recommendations<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Site of Hemorrhage/Clinical Situation</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Desired Factor VIII Peak Level</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Duration<sup>b</sup></b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>WFH = World Federation of Hemophilia; (WFH [Srivastava 2020]).</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>b</sup> Depending on procedure; the number of doses would depend on the half-life of the clotting factor concentrate (CFC) used.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>c</sup> May be longer if response is inadequate.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>d</sup> A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>e </sup>Sometimes longer as secondary prophylaxis during physical therapy.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Joint</p></td>
<td align="left">
<p style="text-indent:0em;">40 to 60 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 2 days<sup>c,d</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Superficial muscle/no neurovascular compromise</p></td>
<td align="left">
<p style="text-indent:0em;">40 to 60 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">2 to 3 days<sup>c</sup></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Iliopsoas or deep muscle with neurovascular injury, or substantial blood loss</p></td>
<td align="left">
<p style="text-indent:0em;">
<i>Initial:</i> 80 to 100 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 2 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30 to 60 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">3 to 5 days<sup>e</sup></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">CNS/Head</p></td>
<td align="left">
<p style="text-indent:0em;">
<i>Initial:</i> 80 to 100 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 7 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">8 to 21 days</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Throat and neck</p></td>
<td align="left">
<p style="text-indent:0em;">
<i>Initial:</i> 80 to 100 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 7 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">8 to 14 days</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Gastrointestinal</p></td>
<td align="left">
<p style="text-indent:0em;">
<i>Initial:</i> 80 to 100 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">7 to 14 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">Not specified</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Renal</p></td>
<td align="left">
<p style="text-indent:0em;">50 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">3 to 5 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Deep laceration</p></td>
<td align="left">
<p style="text-indent:0em;">50 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">5 to 7 days</p></td></tr>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;">Surgery (major)</p></td>
<td align="left">
<p style="text-indent:0em;">
<i>Preop:</i> 80 to 100 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">Single dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Postop:</i> 60 to 80 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 3 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Postop:</i> 40 to 60 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">4 to 6 days</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Postop:</i> 30 to 50 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">7 to 14 days</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Surgery (minor)</p></td>
<td align="left">
<p style="text-indent:0em;">
<i>Preop:</i> 50 to 80 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">Single dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Postop:</i> 30 to 80 units/dL</p></td>
<td align="left">
<p style="text-indent:0em;">1 to 5 days</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 2:</b> Calculate dose using desired peak factor VIII level from step 1 and the following equation:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Formula for units required to raise blood level:</i></p>
<p style="text-indent:-2em;margin-left:12em;">Factor VIII units required = ([desired peak factor VIII level − patient's baseline factor VIII level] × body weight [kg])/2</p>
<p style="text-indent:-2em;margin-left:12em;">Example for 25 kg patient with a desired peak factor VIII level of 35 units/dL and baseline factor VIII level of 5 units/dL:</p>
<p style="text-indent:-2em;margin-left:12em;">Factor VIII units required = (35 units/dL − 5 units/dL) × 25 kg/2 = 375 units of factor VIII</p>
<p style="text-indent:-2em;margin-left:12em;">
<b>Note:</b> Factor VIII level units are units/dL.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 3:</b> Determine the frequency of repeat dosing based on half-life of product used (see product-specific labeling for details), type of bleed or surgery, and patient response. If subsequent factor VIII levels are available for individual patients these should be taken into consideration when determining the frequency of repeat dose.</p>
<table border="1" frame="border" rules="all" style="margin-left:10em;">
<caption style="text-align:left;">
<b>Antihemophilic Factor (Recombinant [Pegylated]) Administration Frequency According to Clinical Scenario</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left" rowspan="2">
<p style="text-indent:0em;">
<b>Product</b></p></th>
<th align="left" colspan="3">
<p style="text-indent:0em;">
<b>Type of Bleeding Event</b></p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">
<b>Type of Surgery</b></p></th></tr>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Minor Severity<sup>a</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Moderate Severity<sup>b</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Major Severity<sup>c</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Minor Bleeding Risk<sup>d</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Major Bleeding Risk<sup>e</sup></b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<sup>a</sup> Minor bleeds include early hemarthrosis, mild muscle bleeding, or mild oral bleeding episode.</p></td></tr>
<tr>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<sup>b</sup> Moderate bleeds include muscle bleeding, moderate bleeding into the oral cavity, definite hemarthroses, and known trauma.</p></td></tr>
<tr>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<sup>c</sup> Major bleeds include significant GI bleeding, intracranial, intra-abdominal or intrathoracic bleeding, CNS bleeding, bleeding in the retropharyngeal or retroperitoneal spaces or iliopsoas sheath, fractures, head trauma.</p></td></tr>
<tr>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<sup>d</sup> Including tooth extraction.</p></td></tr>
<tr>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<sup>e</sup> For example: Intracranial, intra-abdominal, or intrathoracic surgery; joint replacement surgery.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Adynovate</p></td>
<td align="left">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Single dose typically adequate; re-dose at 24 hours if needed</p></td>
<td align="left">
<p style="text-indent:0em;">Every 8 to 24 hours; patients &lt;12 years may require more frequent dosing every 6 to 24 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Esperoct</p></td>
<td align="left">
<p style="text-indent:0em;">Single dose typically adequate</p></td>
<td align="left">
<p style="text-indent:0em;">An additional dose may be administered after 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 24 hours if needed</p></td>
<td align="left">
<p style="text-indent:0em;">Every 24 hours; after the first week extend to every 48 hours until wound healing has occurred</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Jivi</p></td>
<td align="left">
<p style="text-indent:0em;">Every 24 to 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 24 to 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Routine prophylaxis to reduce the frequency of bleeding episodes</i>: Note:</b> Maintain trough factor VIII levels &gt;3% to 5% or higher as clinically indicated based on level of activity, lifestyle, and pharmacokinetics. Dose escalation should be considered for patients adherent to prescribed prophylaxis but still experiencing breakthrough bleeding events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Product-specific dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">Adynovate:</p>
<p style="text-indent:-2em;margin-left:10em;">Children &lt;12 years: IV: 55 units/kg/dose twice weekly; adjust dose and dosing interval based on clinical response; maximum dose: 70 units/kg/dose.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: IV: 40 to 50 units/kg/dose twice weekly; adjust dose based on clinical response.</p>
<p style="text-indent:-2em;margin-left:8em;">Esperoct:</p>
<p style="text-indent:-2em;margin-left:10em;">Children &lt;12 years: IV: 65 units/kg/dose twice weekly; adjust dose and dosing interval based on clinical response.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: IV: 50 units/kg/dose every 4 days; adjust dose and dosing interval based on clinical response.</p>
<p style="text-indent:-2em;margin-left:8em;">Jivi: Children ≥12 years and Adolescents: IV: 30 to 40 units/kg/dose twice weekly; based on bleeding episodes, the dose may be adjusted to 45 to 60 units/kg/dose every 5 days, then may be further adjusted to less or more frequent dosing based on clinical response.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51064854"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51064855"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F45760119"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="105442" href="/d/html/105442.html" rel="external">see "Factor VIII, recombinant human pegylated: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be400ab4-381a-4d5e-b65d-e32a52f7ab49">Hemophilia A, without inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A, without inhibitors:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment and control of bleeding episodes or perioperative management:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent IV bolus dosing: </i>
<b>IV:</b> Utilize steps 1 to 3 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 1:</b> Determine desired factor VIII peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. Selection of the lower-dose practice pattern requires closer observation with the potential for requiring escalation to higher doses based on clinical response.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For patients without inhibitors and receiving emicizumab who experience breakthrough bleeding, antihemophilic factor (recombinant [pegylated]) should be dosed to target the desired peak factor VIII levels outlined in the table as emicizumab is not indicated for treatment of bleeding episodes.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption>
<b>Antihemophilic Factor (Recombinant [Pegylated]) World Federation of Hemophilia Treatment Recommendations<sup>d</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="bottom">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Type of hemorrhage or surgery</b></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">
<b>Lower-dose practice pattern</b></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">
<b>Higher-dose practice pattern</b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Desired peak factor VIII level (units/dL)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Treatment duration (days)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Desired peak factor VIII level (units/dL)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Treatment duration (days)</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="55">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>May be longer if response is inadequate.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Sometimes longer as secondary prophylaxis during physical therapy.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>WFH [Srivastava 2020].</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Joint</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>a,c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>a,c</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Superficial muscle/no neurovascular compromise (except iliopsoas)</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>a</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Iliopsoas or deep muscle with neurovascular injury or substantial blood loss: </b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>b</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Intracranial:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 21</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Throat and neck:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Gastrointestinal:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Renal</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Deep laceration</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (major):</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Preop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Postop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center" colspan="55">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (minor):</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Preop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 2:</b> Calculate dose using desired peak factor VIII level from step 1 and the following equation:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII units required = [(desired peak factor VIII level − patient's baseline factor VIII level) × body weight (kg)]/2</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Factor VIII level units are units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">Example for 50 kg patient with desired peak factor VIII level of 35 units/dL and baseline factor VIII level of 5 units/dL:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII units required = [(35 units/dL − 5 units/dL) × 50 kg]/2 = 750 units of factor VIII</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 3:</b> Determine need for repeat dosing based on manufacturer's recommended frequency of repeat dosing. <b>Note:</b> Frequency of administration must also take into consideration subsequent factor VIII activity measurements and the clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption>
<b>Antihemophilic Factor (Recombinant [Pegylated]) Administration Frequency According to Clinical Scenario</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="bottom">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Product</p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">Bleeding event</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Surgery</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Minor severity</p></th>
<th align="center">
<p style="text-indent:0em;">Moderate severity</p></th>
<th align="center">
<p style="text-indent:0em;">Major severity</p></th>
<th align="center">
<p style="text-indent:0em;">Minor bleeding risk</p></th>
<th align="center">
<p style="text-indent:0em;">Major bleeding risk</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Adynovate</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose typically adequate; re-dose at 24 hours if needed</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Esperoct</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose typically adequate</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Jivi</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 to 48 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 to 48 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;margin-top:2em;">
<i>Continuous infusion dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-27704637','lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-27704637','lexi-content-ref-32744769'])">Ref</a></span>)</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Continuous infusion administration is preferred over intermittent bolus administration for patients requiring prolonged treatment courses (eg, postoperative management after surgery with major bleeding risk). To ensure safe and effective use, only products with extended stability information should be used. Extended stability information may not be available for all products; contact product manufacturer to obtain current recommendations. Use of a smart infusion pump with small volume infusion capability is also necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> Administer an initial bolus to achieve the desired factor VIII level (see steps 1 and 2 under intermittent bolus dosing), then initiate continuous infusion at 2 to 4 units/kg/hour. Adjust dose based on frequent factor assays (at least daily) and calculation of factor VIII clearance at steady-state using the below equations.</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (measured factor VIII level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">New infusion rate (units/kg/hour) = (factor VIII clearance in mL/kg/hour) × (desired factor VIII level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> With infusion dose increases, re-bolus should be considered to achieve target factor VIII level more quickly. See steps 1 and 2 under intermittent bolus dosing to determine re-bolus dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Routine prophylaxis to reduce the frequency of bleeding episodes:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Preferably, dosing should be tailored to ensure trough factor VIII levels of at least 1% and ideally ≥3% to 5% are achieved, but prophylaxis targets should be tailored to individual level of activity, lifestyle, and pharmacokinetics. Dose escalation should be considered for patients adherent to prescribed prophylaxis but still experiencing breakthrough bleeding events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adynovate: <b>IV:</b> 40 to 50 units/kg/dose twice weekly; adjust dose based on clinical response.</p>
<p style="text-indent:-2em;margin-left:6em;">Esperoct: <b>IV:</b> 50 units/kg/dose every 4 days; adjust dose based on clinical response.</p>
<p style="text-indent:-2em;margin-left:6em;">Jivi: <b>IV:</b> 30 to 40 units/kg/dose twice weekly; adjust dose to 45 to 60 units/kg every 5 days, then may be further adjusted to less or more frequent dosing based on clinical response. Maximum dose per infusion (according to Jivi manufacturer): ~6,000 units (rounded to vial size).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990613"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987770"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F45692632"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (2% to 14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (2%), pruritus (2%), skin rash (≤5%), urticaria (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3% to 4%), diarrhea (7%), dysgeusia (1%), nausea (≤5%), vomiting (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≤4%, including severe hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1% to 2%), insomnia (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (7% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (5% to 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritic rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Ocular hyperemia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F45650194"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylactic reaction) to antihemophilic factor (recombinant [pegylated]), antihemophilic factor (recombinant), mouse or hamster protein, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F45760110"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Formation of antibodies (inhibitors) to factor VIII may occur; monitor patients for the development of antibodies by clinical observation and laboratory tests. Suspect factor VIII antibodies if the plasma factor VIII level does not increase as expected or if bleeding is not controlled after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, have occurred. Angioedema, chest tightness, dyspnea, nausea, pruritus, urticaria, vomiting, and wheezing may progress to anaphylaxis. Discontinue immediately and institute appropriate treatment if hypersensitivity reactions occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Mouse/hamster protein: Products may contain trace amounts of mouse or hamster protein.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polyethylene glycol: Products contain polyethylene glycol (PEG). A clinical immune response associated with IgM anti-PEG antibodies, manifested as symptoms of acute hypersensitivity and/or loss of drug effect, has been observed (primarily in patients &lt;6 years of age) with Jivi. In case of clinical suspicion of loss of drug effect, test for factor VIII inhibitors and factor VIII recovery. A low postinfusion factor VIII level in the absence of detectable factor VIII inhibitors likely indicates anti-PEG antibodies; discontinue Jivi and switch patients to a previously effective factor VIII product. A similar clinical immune response has not been observed with Adynovate or Esperoct.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: May contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dose requirements: The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F57945559"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Allergic-type hypersensitivity reactions including anaphylaxis may occur; discontinue therapy immediately if urticaria, hives, hypotension, tightness of the chest, wheezing, or anaphylaxis develop; emergency treatment and resuscitative measures (eg, epinephrine, oxygen) may be needed. Clinical response to antihemophilic factor administration may vary; dosage must be individualized based on coagulation studies (performed prior to treatment and at regular intervals during treatment) and clinical response. If bleeding is not controlled with the recommended dose, determine plasma level of factor VIII and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor VIII fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate. Formation of factor VIII inhibitors (neutralizing antibodies to antihemophilic factor) may occur at any time; in general, formation of inhibitors are more common in young children with severe hemophilia during the first years of therapy, or in patients at any age who received little prior therapy with factor VIII; monitor patients appropriately (WFH [Srivastava 2020]).</p></div>
<div class="block dosfc drugH1Div" id="F50640544"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>
<div class="block foc drugH1Div" id="F45755754"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adynovate: ~250 units (1 ea); ~3000 units (1 ea); ~2000 units (1 ea); ~1500 units (1 ea); ~1000 units (1 ea); ~750 units (1 ea); ~500 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Esperoct: antihemophilic factor (recombinant) glycopegylated-exei ~500 units (1 ea); antihemophilic factor (recombinant) glycopegylated-exei ~3000 units (1 ea); antihemophilic factor (recombinant) glycopegylated-exei ~2000 units (1 ea); antihemophilic factor (recombinant) glycopegylated-exei ~1500 units (1 ea); antihemophilic factor (recombinant) glycopegylated-exei ~1000 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jivi: ~500 units (1 ea); ~1000 units (1 ea); ~2000 units (1 ea); ~3000 units (1 ea) [latex free; contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F45755752"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F51949128"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Esperoct Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $3.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $3.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500 unit (Price provided is per AHF Unit): $3.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $3.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (Price provided is per AHF Unit): $3.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Jivi Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $3.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $3.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $3.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (Price provided is per AHF Unit): $3.31</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872103"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adynovate: ~250 units (1 ea); ~3000 units (1 ea); ~2000 units (1 ea); ~1500 units (1 ea); ~1000 units (1 ea); ~500 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Esperoct: 500 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jivi: ~500 units (1 ea); ~1000 units (1 ea); ~2000 units (1 ea); ~3000 units (1 ea) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52617433"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV:</p>
<p style="text-indent:-2em;margin-left:2em;">Adynovate: Children and Adolescents: Infuse IV over ≤5 minutes; maximum infusion rate: 10 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Esperoct: Children and Adolescents: Infuse IV over approximately 2 minutes. <b>Note:</b> Some needleless connectors may be incompatible with the Esperoct syringe; refer to the manufacturer's labeling for administration instructions if using an incompatible needleless connector.</p>
<p style="text-indent:-2em;margin-left:2em;">Jivi: Children ≥12 years and Adolescents: Infuse IV over 1 to 15 minutes; adjust rate to individual patient response not to exceed a maximum infusion rate: 2.5 mL/minute.</p></div>
<div class="block adm drugH1Div" id="F45760125"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adynovate: Infuse over ≤5 minutes (maximum infusion rate: 10 mL/minute).</p>
<p style="text-indent:-2em;margin-left:4em;">Esperoct: Infuse over ~2 minutes. <b>Note:</b> Some needleless connectors may be incompatible with the Esperoct syringe; refer to the manufacturer's labeling for administration instructions if using an incompatible needleless connector.</p>
<p style="text-indent:-2em;margin-left:4em;">Jivi: Infuse over 1 to 15 minutes (maximum infusion rate: 2.5 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Continuous infusion (off-label rate):</b> Has also been administered as a continuous infusion to avoid peaks and troughs associated with intermittent infusions in patients who require prolonged treatment periods. Use a smart infusion pump with small volume infusion capability. Refer to protocols for product selection and preparation details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-27704637','lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-27214734','lexi-content-ref-27704637','lexi-content-ref-32744769'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F45760112"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Adynovate: Store intact vials at 2°C to 8°C (36°F to 46°F) in original package to protect from extreme exposure to light. Do not freeze. May also store up to 30°C (86°F) for ≤3 months. After storage at room temperature, do not return to refrigerator. Following reconstitution, use immediately or may store at room temperature ≤3 hours before administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Esperoct: Store intact vials at 2°C to 8°C (36°F to 46°F) in original package to protect from light. Do not freeze. May also store up to 30°C (86°F) for ≤12 months or up to 40°C (104°F) for ≤3 months. After storage at room temperature, do not return to refrigerator. Following reconstitution, use immediately or may store solution in vial with vial adaptor and syringe attached at room temperature (≤30°C [≤86°F]) for ≤4 hours or refrigerated (2°C to 8°C [36°F to 46°F]) for ≤24 hours before administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Jivi: Store intact vials at 2°C to 8°C (36°F to 46°F) in original package to protect from extreme exposure to light. Do not freeze. May also store up to 25°C (77°F) for ≤6 months. After storage at room temperature, do not return to refrigerator. Following reconstitution, use immediately or may store at room temperature for ≤3 hours before administration.</p></div>
<div class="block usep drugH1Div" id="F57945558"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Adynovate, Esperoct: Treatment of hemophilia A (congenital factor VIII deficiency) in any of the following: On-demand treatment and control of bleeding episodes; perioperative management; routine prophylaxis to reduce the frequency of bleeding episodes (All indications: FDA approved in ages ≥1 year and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Jivi: Treatment of previously treated patients with hemophilia A in any of the following: On-demand treatment and control of bleeding episodes; perioperative management; routine prophylaxis to reduce the frequency of bleeding episodes (All indications: FDA approved in ages ≥12 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Antihemophilic factor (recombinant [pegylated]) is not indicated for the treatment of von Willebrand disease.</p></div>
<div class="block cyt drugH1Div" id="F45730334"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F45730331"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Pegloticase: May diminish the therapeutic effect of PEGylated Drug Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvaliase: PEGylated Drug Products may enhance the adverse/toxic effect of Pegvaliase. Specifically, the risk of anaphylaxis or hypersensitivity reactions may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F45760108"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pregnant carriers of hemophilia A may have an increased bleeding risk following invasive procedures, spontaneous miscarriage, termination of pregnancy, and delivery; close surveillance is recommended. Factor VIII levels should be monitored at the first antenatal visit, once or twice during the third trimester, prior to surgical or invasive procedures, and at delivery. Although factor VIII concentrations increase in pregnant patients, factor VIII replacement is recommended if concentrations are &lt;50 units/dL and any of the following occur: need for invasive procedures (including delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or active bleeding. Hemostatic factor VIII concentrations should be maintained for at least 3 to 5 days following invasive procedures or postpartum. If a replacement product is indicated, a recombinant product is preferred (NHF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]). Initial reports using the recombinant pegylated product have been limited to use in males (Brand 2016; Dunn 2018; Konkle 2015).</p></div>
<div class="block mopp drugH1Div" id="F57945622"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Factor VIII levels prior to and during treatment; typically during treatment of an acute bleeding event or in the perioperative setting, factor VIII levels should be measured as peaks 15 to 30 minutes after infusion to assess target level achievement (WFH [Srivastava 2020]). <b>Note:</b> The World Federation of Hemophilia (WFH) recommends use of a chromogenic factor VIII activity assay or one-stage aPTT-based assay with a validated reagent, calibrated with a plasma standard traceable to a WHO international standard for monitoring Esperoct and Jivi; for Adynovate, WFH advises that more laboratory assay studies are required to inform recommendations about laboratory monitoring (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Heart rate and blood pressure before and during IV administration; signs and symptoms of bleeding, hemoglobin and hematocrit, and signs and symptoms of hypersensitivity reactions; monitor for the development of inhibitor antibodies by clinical observations (eg, inadequate control of bleeding with adequate doses) and laboratory tests (eg, inhibitor level, Bethesda assay).</p></div>
<div class="block rerp drugH1Div" id="F57945623"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Classification of hemophilia (WFH [Srivastava 2020]):</p>
<p style="text-indent:-2em;margin-left:4em;">Severe: Factor level &lt;1% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate: Factor level 1% to 5% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild: Factor level 5% to &lt;40% of normal.</p></div>
<div class="block pha drugH1Div" id="F45760114"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Factor VIII replacement, necessary for clot formation and maintenance of hemostasis, activates factor X in conjunction with activated factor IX. Activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot.</p></div>
<div class="block phk drugH1Div" id="F45760116"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pharmacokinetic data for Adynovate are based on a single dose of 45 units/kg and plasma factor VIII activity measured by one-stage assay. Pharmacokinetic data for Esperoct are based on a single dose of 50 units/kg and plasma factor VIII activity measured by one-stage assay. Pharmacokinetic data for Jivi are based on combined data for single doses of 25 units/kg and 60 units/kg and plasma factor VIII activity measured by one-stage assay.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Adynovate: Children &lt;6 years of age: 0.56 ± 0.12 dL/kg; Children 6 to &lt;12 years of age: 0.54 ± 0.09 dL/kg; Children and Adolescents 12 to &lt;18 years of age: 0.56 ± 0.18 dL/kg; Adults ≥18 years of age: 0.43 ± 0.11 dL/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Esperoct: Children &lt;6 years of age: 44.2 mL/kg; Children 6 to &lt;12 years of age: 47.3 mL/kg; Children and Adolescents 12 to &lt;18 years of age: 36.4 mL/kg; Adults ≥18 years of age: 37.3 mL/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Jivi: Children ≥12 years of age, Adolescents, and Adults: 36 ± 6.5 to 44.7 ± 5.4 mL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Adynovate: Children &lt;6 years of age: 11.8 ± 2.43 hours; Children 6 to &lt;12 years of age: 12.4 ± 1.67 hours; Children and Adolescents 12 to &lt;18 years of age: 13.43 ± 4.05 hours; Adults ≥18 years of age: 14.69 ± 3.79 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Esperoct: Children &lt;6 years of age: 14.7 hours; Children 6 to &lt;12 years of age: 13.8 hours; Children and Adolescents 12 to &lt;18 years of age: 17.4 hours; Adults ≥18 years of age: 21.7 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Jivi: Children ≥12 years of age, Adolescents, and Adults: 17.4 ± 3.8 to 21.4 ± 13.1 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Adynovate: Children and Adolescents 12 to &lt;18 years of age: 0.26 ± 0.1 hours; Adults ≥18 years of age: 0.46 ± 0.29 hours.</p></div>
<div class="block phksp drugH1Div" id="F54126264"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Obesity: Esperoct: Incremental recovery increased by ~17% and 41%, AUC increased by ~10% and 27%, and clearance decreased by ~8% and 23% in adult patients with a BMI of 25 to &lt;30 kg/m<sup>2</sup> and 30 to &lt;35 kg/m<sup>2</sup>, respectively, in comparison to subjects with a BMI &lt;25 kg/m<sup>2</sup>.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49940051"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Adynovate</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Adynovate</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Adynovate</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Adynovate</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Adynovate</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adynovate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adynovate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Adynovate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Adynovate | Jivi</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Adynovate</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Adynovi</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Adynovate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Adynovate.1">
<a name="Adynovate.1"></a>Adynovate (antihemophilic factor [recombinant (pegylated)]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12010406">
<a name="12010406"></a>Batorova A, Martinowitz U. Continuous infusion of coagulation factors. <i>Haemophilia</i>. 2002;8(3):170-177. doi:10.1046/j.1365-2516.2002.00635.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/12010406/pubmed" id="12010406" target="_blank">12010406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530687">
<a name="22530687"></a>Batorova A, Holme P, Gringeri A, et al; European Haemophilia Treatment Standardisation Board. Continuous infusion in haemophilia: current practice in Europe. <i>Haemophilia</i>. 2012;18(5):753-759. doi:10.1111/j.1365-2516.2012.02810.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/22530687/pubmed" id="22530687" target="_blank">22530687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27328112">
<a name="27328112"></a>Brand B, Gruppo R, Wynn TT. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients. <i>Haemophilia</i>. 2016;22(4):e251-e258. doi: 10.1111/hae.12963.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/27328112/pubmed" id="27328112" target="_blank">27328112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29359417">
<a name="29359417"></a>Dunn AL, Ahuja SP, Mullins ES. Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A. <i>Haemophilia</i>. 2018;24(3):e84-e92. doi: 10.1111/hae.13403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/29359417/pubmed" id="29359417" target="_blank">29359417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Esperoct.1">
<a name="Esperoct.1"></a>Esperoct (antihemophilic factor [recombinant (pegylated)]) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Esperoct.2">
<a name="Esperoct.2"></a>Esperoct (antihemophilic factor [recombinant (pegylated)]) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23645693">
<a name="23645693"></a>Henrard S, Speybroeck N, Hermans C. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. <i>Haematologica</i>. 2013;98(9):1481-1486. doi: 10.3324/haematol.2013.084038.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/23645693/pubmed" id="23645693" target="_blank">23645693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28873263">
<a name="28873263"></a>Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. <i>Haemophilia</i>. 2018;24(1):24-32. doi:10.1111/hae.13331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/28873263/pubmed" id="28873263" target="_blank">28873263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jivi.1">
<a name="Jivi.1"></a>Jivi (antihemophilic factor [recombinant {pegylated}]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26157075">
<a name="26157075"></a>Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. <i>Blood</i>. 2015;126(9):1078-1085.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/26157075/pubmed" id="26157075" target="_blank">26157075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1482660">
<a name="1482660"></a>Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. <i>Br J Haematol</i>. 1992;82(4):729-734. doi:10.1111/j.1365-2141.1992.tb06951.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/1482660/pubmed" id="1482660" target="_blank">1482660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29039750">
<a name="29039750"></a>McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton AN. Modeling of body weight metrics for effective and cost-efficient conventional factor VIII dosing in hemophilia A prophylaxis. <i>Pharmaceutics</i>. 2017;9(4):47. doi: 10.3390/pharmaceutics9040047.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/29039750/pubmed" id="29039750" target="_blank">29039750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHF.1">
<a name="NHF.1"></a>National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). https://www.hemophilia.org/node/3660. Published September 17, 2017. Accessed June 7, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22503305">
<a name="22503305"></a>Poon MC, Card R. Hemophilia management in transfusion medicine. <i>Transfus Apher Sci</i>. 2012;46(3):299-307. doi:10.1016/j.transci.2012.03.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/22503305/pubmed" id="22503305" target="_blank">22503305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27214734">
<a name="27214734"></a>Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. <i>Haemophilia</i>. 1995;1(suppl 1):8-13. doi:10.1111/j.1365-2516.1995.tb00104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/27214734/pubmed" id="27214734" target="_blank">27214734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744769">
<a name="32744769"></a>Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27704637">
<a name="27704637"></a>Suzuki N, Hirakawa A, Kishimoto M, et al. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. <i>Haemophilia</i>. 2017;23(2):215-221. doi:10.1111/hae.13082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/27704637/pubmed" id="27704637" target="_blank">27704637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31887776">
<a name="31887776"></a>Tiede A, Cid AR, Goldmann G, et al. Body mass index best predicts recovery of recombinant factor VIII in underweight to obese patients with severe haemophilia A. <i>Thromb Haemost</i>. 2020;120(2):277-288. doi: 10.1055/s-0039-3400745.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-pediatric-drug-information/abstract-text/31887776/pubmed" id="31887776" target="_blank">31887776</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 141008 Version 13.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
